Riechelmann Rachel P, Krzyzanowska Monika K, Zimmermann Camilla
Department of Internal Medicine, Federal University of Sao Paulo, R: Luisiania 255, Apt 11, São Paulo, SP 04560-020, Brazil.
Support Care Cancer. 2009 Jun;17(6):745-8. doi: 10.1007/s00520-008-0541-y. Epub 2008 Nov 22.
Cancer patients usually take many medications. The proportion of patients with advanced cancer who are taking futile drugs is unknown.
We retrospectively reviewed the charts of all consecutive ambulatory patients with advanced cancer and who were receiving supportive care exclusively at palliative care clinics, Princess Margaret Hospital, to gather information on futile medications used by them. Futile medications were defined as unnecessary (when no short-term benefit to patients with respect to survival, quality of life, or symptom control was anticipated) or duplicate (two or more drugs from the same pharmacological class). Summary statistics were used to describe the results.
From November 2005 to July 2006, 82 (22%) of 372 patients were taking at least one futile medication before consultation; after initial consultation, this proportion dropped to 20% (78): 70 patients were taking unnecessary medications, while eight were on duplicate medications. The most frequent unnecessary medications used by patients were statins (56%). The most common duplicate medication involved the use of two different benzodiazepines (seven patients).
About one fifth of cancer outpatients at the end of life take futile medications, most commonly statins. Prospective and population-based studies are warranted to further evaluate the magnitude and consequences of futile medication use in oncology.
癌症患者通常服用多种药物。晚期癌症患者中服用无效药物的比例尚不清楚。
我们回顾性分析了玛格丽特公主医院姑息治疗诊所所有连续就诊的晚期癌症门诊患者的病历,这些患者仅接受支持性治疗,以收集他们使用无效药物的信息。无效药物被定义为不必要的(即预期对患者的生存、生活质量或症状控制没有短期益处)或重复的(来自同一药理类别的两种或更多药物)。使用汇总统计数据来描述结果。
2005年11月至2006年7月,372例患者中有82例(22%)在会诊前至少服用一种无效药物;初次会诊后,这一比例降至20%(78例):70例患者服用不必要的药物,8例患者服用重复药物。患者最常使用的不必要药物是他汀类药物(56%)。最常见的重复用药情况是使用两种不同的苯二氮䓬类药物(7例患者)。
约五分之一的晚期癌症门诊患者服用无效药物,最常见的是他汀类药物。有必要进行前瞻性和基于人群的研究,以进一步评估肿瘤学中无效药物使用的程度和后果。